KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

AbCellera Biologics (ABCL) Net Income towards Common Stockholders (2020 - 2026)

AbCellera Biologics filings provide 7 years of Net Income towards Common Stockholders readings, the most recent being -$43.2 million for Q1 2026.

  • Quarterly Net Income towards Common Stockholders rose 5.38% to -$43.2 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$144.0 million through Mar 2026, up 14.24% year-over-year, with the annual reading at -$146.4 million for FY2025, 10.1% up from the prior year.
  • Net Income towards Common Stockholders hit -$43.2 million in Q1 2026 for AbCellera Biologics, down from -$8.9 million in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at $168.6 million in Q1 2022 and bottomed at -$57.1 million in Q3 2025.
  • Average Net Income towards Common Stockholders over 5 years is -$20.0 million, with a median of -$34.7 million recorded in 2025.
  • The largest annual shift saw Net Income towards Common Stockholders surged 224.53% in 2022 before it tumbled 349.93% in 2023.
  • AbCellera Biologics' Net Income towards Common Stockholders stood at -$29.9 million in 2022, then crashed by 57.73% to -$47.2 million in 2023, then grew by 27.44% to -$34.2 million in 2024, then soared by 73.85% to -$8.9 million in 2025, then crashed by 382.56% to -$43.2 million in 2026.
  • Per Business Quant, the three most recent readings for ABCL's Net Income towards Common Stockholders are -$43.2 million (Q1 2026), -$8.9 million (Q4 2025), and -$57.1 million (Q3 2025).